Patents by Inventor Marc GLEESON
Marc GLEESON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240158375Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: October 20, 2021Publication date: May 16, 2024Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Robert M. BURK, Marc GLEESON, Mark Richard STEWART, Soultana KATSINA
-
Publication number: 20230399317Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: October 20, 2021Publication date: December 14, 2023Inventors: Charles BOSWORTH, Mark Richard STEWART, Hila BARASH, Nicholas Andrew CHAPMAN, Robert M. BURK, Ian HOLMES, Marc GLEESON, Yair ALSTER, Omer RAFAELI, Jonathan DUNN
-
Publication number: 20230357207Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: March 8, 2023Publication date: November 9, 2023Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Robert M. BURK, Jonathan DUNN, Nicholas CHAPMAN
-
Publication number: 20230348517Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: March 6, 2023Publication date: November 2, 2023Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN
-
Patent number: 11643429Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: April 5, 2021Date of Patent: May 9, 2023Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn
-
Patent number: 11634411Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: December 4, 2020Date of Patent: April 25, 2023Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
-
Publication number: 20230000675Abstract: Provided herein are devices and methods for applying a medicament to an eyelid, e.g. eyelid margin, of a patient while protecting the adjunct ocular tissues such as the cornea.Type: ApplicationFiled: July 6, 2022Publication date: January 5, 2023Inventors: Yair ALSTER, Omer RAFAELI, Marc GLEESON, Charles BOSWORTH, Eitan SHARIFF, Dan TEBOUL
-
Publication number: 20220332749Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: June 15, 2022Publication date: October 20, 2022Inventors: Ian HOLMES, Yair ALSTER, Hila EPSTEIN-BARASH, Charles BOSWORTH, Omer RAFAELI, Robert M. BURK, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN, Alexander James NICHOLLS
-
Publication number: 20220332748Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: April 5, 2021Publication date: October 20, 2022Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Robert M. BURK, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN, Alexander James NICHOLLS
-
Publication number: 20220323487Abstract: Provided herein are pharmaceutical compositions and methods treating Demodex or a disorder thereof around the eye by application of a metered dose of a semi-solid product from a product tube.Type: ApplicationFiled: May 2, 2022Publication date: October 13, 2022Inventors: Omer RAFAELI, Charles BOSWORTH, Marc GLEESON, Yair ALSTER, Hadas RAPAPORT
-
Patent number: 11459351Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: April 5, 2021Date of Patent: October 4, 2022Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Robert M. Burk, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn, Alexander James Nicholls
-
Publication number: 20220233584Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).Type: ApplicationFiled: April 18, 2022Publication date: July 28, 2022Inventors: Charles BOSWORTH, Yair ALSTER, Hila EPSTEIN-BARASH, Omer RAFAELI, Marc GLEESON
-
Patent number: 11324775Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).Type: GrantFiled: June 24, 2021Date of Patent: May 10, 2022Assignee: AZURA OPHTHALMICS LTD.Inventors: Charles Bosworth, Yair Alster, Hila Epstein-Barash, Omer Rafaeli, Marc Gleeson
-
Publication number: 20210315926Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).Type: ApplicationFiled: June 24, 2021Publication date: October 14, 2021Inventors: Charles BOSWORTH, Yair ALSTER, Hila EPSTEIN-BARASH, Omer RAFAELI, Marc GLEESON
-
Publication number: 20210230205Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: April 5, 2021Publication date: July 29, 2021Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN
-
Publication number: 20210107899Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: December 4, 2020Publication date: April 15, 2021Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Robert M. BURK, Jonathan DUNN, Nicholas CHAPMAN
-
Patent number: 10875845Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: June 17, 2020Date of Patent: December 29, 2020Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
-
Publication number: 20200331896Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: ApplicationFiled: June 17, 2020Publication date: October 22, 2020Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Robert M. BURK, Jonathan DUNN, Nicholas CHAPMAN